GenomePrecision
Beijing · Founded 2015
About GenomePrecision
Genomeprecision is a molecular diagnostic enterprise integrating R&D, production and sales. It has established “real-time fluorescent quantitative PCR”, “first-generation Sanger sequencing”, “second-generation high-throughput NGS sequencing” and “capillary electrophoresis”. "Fragment Analysis" and "Chemiluminescence CLIA" five molecular diagnostic technology platforms, we will be based on clinical diagnosis and treatment needs to develop molecular diagnostic products based on the above technology platform.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $45.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Apr 2021)
- Website: genomeprecision.com
- Phone: 010-56380026
Industries & Categories
Biotechnology, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/genomeprecision-87428 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.